Shandong Weigao Group Medical Polymer Company Limited (WEIGAO GROUP) reported a minor share repurchase on 14 September 2026, according to its latest Next Day Disclosure Return filed with the Hong Kong Stock Exchange.

Key transaction details • Date and venue: 14 September 2026, on the HKEX trading platform • Volume: 24,400 H-shares, representing 0.0005% of the company’s 4.46 billion issued shares (excluding treasury shares) as of 11 September 2026 • Price range: HK$3.085–HK$3.090 per share • Volume-weighted average price: HK$3.0859 • Aggregate consideration: HK$0.08 million

Capital structure post-transaction (14 September 2026) • Issued shares (excluding treasury): 4.46 billion • Treasury shares: 64.83 million • Total issued shares (including treasury): 4.52 billion

Repurchase mandate utilisation • Mandate size (approved 29 May 2026): up to 446.46 million shares • Shares bought back under the mandate to date: 7.50 million, equal to 1.68% of the issued share count on the mandate date • Remaining authority: approximately 438.96 million shares

Regulatory status The board confirmed that the repurchase complied with all applicable listing rules and legal requirements. A 30-day moratorium on new share issues or treasury share disposals is in force until 15 October 2026, in line with Hong Kong Listing Rules.